[HTML][HTML] Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation
HC Yu, CS Lin, WT Tai, CY Liu, CW Shiau… - Journal of Biological …, 2013 - ASBMB
Hepatocellular carcinoma (HCC) is the most common liver cancer and the third-leading
cause of cancer death worldwide. Nilotinib is an orally available receptor tyrosine kinase
inhibitor approved for chronic myelogenous leukemia. This study investigated the effect of
nilotinib on HCC. Nilotinib did not induce cellular apoptosis. Instead, staining with acridine
orange and microtubule-associated protein 1 light chain 3 revealed that nilotinib induced
autophagy in a dose-and time-dependent manner in HCC cell lines, including PLC5, Huh-7 …
cause of cancer death worldwide. Nilotinib is an orally available receptor tyrosine kinase
inhibitor approved for chronic myelogenous leukemia. This study investigated the effect of
nilotinib on HCC. Nilotinib did not induce cellular apoptosis. Instead, staining with acridine
orange and microtubule-associated protein 1 light chain 3 revealed that nilotinib induced
autophagy in a dose-and time-dependent manner in HCC cell lines, including PLC5, Huh-7 …